A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Exclusion Criteria

• •Have type 1 diabetes (T1D)
• •Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma
• •Have had any myocardial infarction (MI), heart failure or cerebrovascular accident (stroke)
• •Have a known clinically significant gastric empty abnormality
• •Have acute or chronic hepatitis
• •Have had chronic or acute pancreatitis
• •Have any self or family history of type 2A or type 2B multiple endocrine neoplasia in the absence of known C-cell hyperplasia
• •Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of Multiple endocrine neoplasia (MEN) 2A or 2B syndrome)
• •Have evidence of significant, active autoimmune abnormality
• •Have evidence of significant, uncontrolled endocrine abnormality
• •Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years
• •Have any hematologic condition that may interfere with HbA1c measurement